MX389961B - Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). - Google Patents

Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Info

Publication number
MX389961B
MX389961B MX2018006422A MX2018006422A MX389961B MX 389961 B MX389961 B MX 389961B MX 2018006422 A MX2018006422 A MX 2018006422A MX 2018006422 A MX2018006422 A MX 2018006422A MX 389961 B MX389961 B MX 389961B
Authority
MX
Mexico
Prior art keywords
solid dispersions
hemeguanylate
sgc
soluble
cyclase stimulator
Prior art date
Application number
MX2018006422A
Other languages
English (en)
Spanish (es)
Inventor
Ahmad Hashash
Antony Dunbar Craig
Vasu Sethuraman
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX389961B publication Critical patent/MX389961B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2018006422A 2015-11-30 2016-11-22 Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). MX389961B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260910P 2015-11-30 2015-11-30
US201662359440P 2016-07-07 2016-07-07
PCT/US2016/063312 WO2017095697A1 (en) 2015-11-30 2016-11-22 Solid dispersions comprising a sgc stimulator

Publications (1)

Publication Number Publication Date
MX389961B true MX389961B (es) 2025-03-20

Family

ID=57590822

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018006422A MX389961B (es) 2015-11-30 2016-11-22 Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MX2022001655A MX2022001655A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MX2022001656A MX2022001656A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022001655A MX2022001655A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MX2022001656A MX2022001656A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Country Status (12)

Country Link
US (4) US20190269619A1 (enExample)
EP (1) EP3383372B1 (enExample)
JP (3) JP6952707B2 (enExample)
KR (1) KR102841419B1 (enExample)
CN (4) CN116637077A (enExample)
AU (1) AU2016364976B2 (enExample)
BR (1) BR112018011154B1 (enExample)
CA (1) CA3006746C (enExample)
EA (1) EA201891315A1 (enExample)
IL (2) IL259493B (enExample)
MX (3) MX389961B (enExample)
WO (1) WO2017095697A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357777B2 (en) 2016-02-01 2022-06-14 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
EA201990236A1 (ru) 2016-07-07 2019-08-30 Сайклерион Терапьютикс, Инк. Новые способы получения стимуляторов растворимой гуанилатциклазы
KR102487872B1 (ko) * 2016-07-07 2023-01-12 사이클리온 테라퓨틱스, 인크. 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법
WO2019055859A1 (en) 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
CN111902410B (zh) * 2018-01-10 2024-04-19 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
WO2019172420A1 (ja) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 医薬組成物
EP3829644A4 (en) * 2018-07-30 2022-05-04 Ricoh Company, Ltd. PROCESS FOR MANUFACTURING PARTICLES AND PARTICLE AND MEDICATION MANUFACTURED BY THE PROCESS
JP7503781B2 (ja) * 2018-07-30 2024-06-21 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
JP7634525B2 (ja) * 2019-09-23 2025-02-21 バイオノミクス リミテッド 治療用製剤およびその使用
CN115175683A (zh) 2019-10-29 2022-10-11 赛克里翁治疗有限公司 用sGC刺激剂治疗糖尿病性肾病
CN116685308A (zh) * 2020-12-18 2023-09-01 Ucb生物制药有限责任公司 无定形固体分散体
EP4376843A1 (en) 2021-07-28 2024-06-05 Cyclerion Therapeutics, Inc. Treatment of hfpef in post-menopausal women with an sgc stimulator
WO2026035689A1 (en) * 2024-08-06 2026-02-12 Catalyst Pharmaceuticals, Inc. Vamorolone solid oral dosage forms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
WO2012122279A1 (en) * 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
CA2861804C (en) * 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
WO2014047111A1 (en) * 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
ES2911276T3 (es) * 2013-03-15 2022-05-18 Cyclerion Therapeutics Inc Estimuladores de sGC
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
EP3194382B1 (en) * 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators

Also Published As

Publication number Publication date
IL290338B1 (en) 2023-01-01
IL290338B2 (en) 2023-05-01
EP3383372A1 (en) 2018-10-10
US20240293324A1 (en) 2024-09-05
JP6952707B2 (ja) 2021-10-20
US20250255821A1 (en) 2025-08-14
WO2017095697A1 (en) 2017-06-08
CN116637077A (zh) 2023-08-25
KR20180086497A (ko) 2018-07-31
JP2022000464A (ja) 2022-01-04
JP7277534B2 (ja) 2023-05-19
CA3006746A1 (en) 2017-06-08
JP7641320B2 (ja) 2025-03-06
MX2022001656A (es) 2022-03-11
EA201891315A1 (ru) 2018-12-28
JP2019501216A (ja) 2019-01-17
AU2016364976A1 (en) 2018-06-14
CN108883071A (zh) 2018-11-23
KR102841419B1 (ko) 2025-08-01
CA3006746C (en) 2024-01-30
US20250017862A1 (en) 2025-01-16
IL259493B (en) 2022-03-01
CN116942616A (zh) 2023-10-27
AU2016364976B2 (en) 2022-08-25
BR112018011154B1 (pt) 2023-09-26
CN116637076A (zh) 2023-08-25
EP3383372B1 (en) 2023-11-01
MX2022001655A (es) 2022-03-11
IL259493A (en) 2018-07-31
JP2023100851A (ja) 2023-07-19
BR112018011154A2 (pt) 2018-11-21
IL290338A (en) 2022-04-01
US20190269619A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
MX2022001656A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
PH12020550745A1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
CL2017001087A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
NZ723151A (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
MY198769A (en) Substituted heterocyclic derivatives as cdk inhibitors
MX2017006649A (es) Derivados de triazolo-pirazinilo utiles como activadores de guanilato ciclasa soluble.
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MY183536A (en) Pharmaceutical compositions comprising azd9291
CL2019000573A1 (es) Composiciones para comprimidos.
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
CY1124397T1 (el) Κρυσταλλικο (2s,4r)-5-(5'-χλωρο-2-φθορο-[1,1'-διφαινυλ] -4-υλ)-2-(αιθοξυμεθυλ)-4-(3-υδροξυϊσοξαζολη-5- καρβοξαμιδο) -2-μεθυλπεντανοϊκο οξυ και χρησεις αυτου
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
MX381323B (es) Derivado de imidazopirimidina e imidazotriazina, y composición farmacéutica que lo comprende.
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)